Table 1.
Mean (± s.d.) half-life values for remacemide and its desglycinyl metabolite, CL/F values for remacemide and AUC values for the desglycinyl metabolite at different stages of the study. The numbers in parenthesis are the numbers of subjects from whom each mean value was determined.
| Day | Remacemide t½ (h) | Desglycinyl metabolite t½ (h) | Remacemide CL/F (l kg−1 h−1) | Remacemide AUC (ng ml−1 h) | Desglycinyl metabolite AUC (ng ml−1 h) |
|---|---|---|---|---|---|
| 11 | 3.29 ± 0.68 (13) | 14.72 ± 2.82 (8) | 1.25 ± 0.32 (13) | 3203 ± 593 (13) | 1532 ± 258(6) |
| 82 | 3.62 ± 0.80 (10) | 13.49 ± 2.98 (11) | 1.18 ± 0.22 (12) | 2236 ± 310 (12) | 692 ± 157 (12) |
| 503 | 2.69 ± 0.33 (11) | 9.61 ± 5.51 (4) | 2.09 ± 0.53 (11) | 1941 ± 401 (11) | 553 ± 281 (3) |
| 574 | 2.70 ± 0.43 (9) | 7.81 and 13.81 (2) | 1.99 ± 0.43 (10) | 1366 ± 263 (10) | 256 ± 91 (9) |
1
Single dose remacemide (300 mg).
2
Steady state remacemide (200 mg b.d.).
3
Single dose remacemide (300 mg) after approximately 6 weeks phenobarbitone dosing.
4
Steady state remacemide (200 mg b.d.) after approximately 7 weeks phenobarbitone dosing.